Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 440-780-3 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vivo
Administrative data
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 16 December 2002 to 01 February 2003
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 003
- Report date:
- 2003
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.12 (Mutagenicity - In Vivo Mammalian Erythrocyte Micronucleus Test)
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- GLP compliance:
- yes
- Type of assay:
- micronucleus assay
Test material
- Test material form:
- solid: particulate/powder
Test animals
- Species:
- mouse
- Strain:
- NMRI
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River, Sulzfeld, Germany.
- Age at study initiation: (6-8 weeks old)
- Weight at study initiation: 27.6 -33.2 g
- Housing:Group housing of 5 animals per sex per cage in labelled polycarbonate cages containing purified sawdust as bedding material (Sawi, Jelu Werk, Rosenberg, Gennany). Paper bedding was provided as nest material (supplied by B.M.l. Helmond, The Netherlands).
- Diet (e.g. ad libitum): Free access to standard pelleted laboratory animal diet, ad libitum
- Water (e.g. ad libitum): Free access to tap-water, ad libitum.
- Acclimation period: Acclimatisation period was at least 5 days before start of treatment
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 ± 3 °C
- Humidity (%): 30-70 %
- Air changes (per hr): 15 air changes per hour
- Photoperiod (hrs dark / hrs light): 12 hours artificial fluorescent light and 12 hours dark per day.
Administration / exposure
- Route of administration:
- intraperitoneal
- Vehicle:
- suspended in corn oil
- Details on exposure:
- The dosing volume was 10 ml/kg body weight.
Doses / concentrationsopen allclose all
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Dose / conc.:
- 50 mg/kg bw/day (nominal)
- Dose / conc.:
- 25 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- Male: 0 mg/kg; No. of animals: 5; Sacrifice time: 24 hours
Male: 25 mg/kg; No. of animals: 5; Sacrifice time: 24 hours
Male: 50 mg/kg; No. of animals: 5; Sacrifice time: 24 hours
Male: 100 mg/kg; No. of animals: 5; Sacrifice time: 24 hours
Male: 100 mg/kg; No. of animals: 5; Sacrifice time: 48 hours
Female: 0 mg/kg; No. of animals: 5; Sacrifice times: 24 hours
Female: 25 mg/kg; No. of animals: 5; Sacrifice times: 24 hours
Female: 50 mg/kg; No. of animals: 5; Sacrifice times: 24 hours
Female: 100 mg/kg; No. of animals: 5; Sacrifice times: 24 hours
Female: 100 mg/kg; No. of animals: 5; Sacrifice times: 48 hours - Control animals:
- yes, concurrent vehicle
- Positive control(s):
- Cyclophosphamide
Examinations
- Details of tissue and slide preparation:
- All slides were randomly coded before examination. An adhesive label with NOTOX study identification number and code was stuck over the marked slide. At first the slides were screened at a magnification of 100 x for regions of suitable technical quality, i.e. where the cells were well spread, undamaged and well
stained. Slides were scored at a magnification of 1000 x. The number of micronucleated polychromatic erythrocytes was counted in 2000 polychromatic erythrocytes. The ratio polychromatic to nomochromatic erythrocytes was determined by counting and differentiating the first 1000 erythrocytes at the same time.
Micronuclei were only counted in polychromatic erythrocytes. Averages and standard deviations were calculated. - Statistics:
- Equivocal results should be clarified by further testing using modification of experimental conditions. A test substance is considered positive in the micronucleus test if:
- It induced a biologically as well as a statistically significant (Wilcoxon Rank Sum Test; two-sided test at P < 0.05) increase in the frequency of micronucleated polychromatic erythrocytes (at any dose or at any sampling time) in the combined data for both sexes or in the data for male or female groups separately.
A test substance is considered negative in the micronucleus test if:
- None of the tested concentrations or sampling times showed a statistically significant (P < 0.05) increase in the incidence of micronucleated polychromatic erythrocytes neither in the combined data for both sexes nor in the data for male or female groups separately. The preceding criteria are not absolute and other modifying factors may enter into the final evaluation decision.
Results and discussion
Test results
- Sex:
- male/female
- Genotoxicity:
- negative
- Toxicity:
- yes
- Remarks:
- Doses producing toxicity:> = 25 mg / µg with lethargy, arched posture Decreased PCE / NCE ratio to 100 mg / µg
- Vehicle controls validity:
- not examined
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- RESULTS OF RANGE-FINDING STUDY
- Dose range: Based on the results of this dose range finding study dose levels of 100, 50 and 25 mg/kg body weight were selected as appropriate doses for the Micronucleus Test.
- Solubility:
- Clinical signs of toxicity in test animals: The following clinical observations were made in the groups treated with 100 mg of test item /kg
body weight:
During the first hour after dosing all animals were lethargic, had a rough coat and a hunched posture.
Within 18 hours after dosing all animals were still lethargic, ten male and four female animals had a rough coat and two female animals also had a hunched posture. Within 42 hours after dosing four males and one female animal had a rough coat, two male and two
female animals had a hunched posture; one female animal also showed ataxia and was lethargic. One male and three female animals recovered from the treatment.
- Evidence of cytotoxicity in tissue analysed:
Applicant's summary and conclusion
- Conclusions:
- It is concluded that the substance is not mutagenic in the micronucleus test under the experimental conditions described in this report.
- Executive summary:
The substance was tested in the Micronucleus Test in mice, to evaluate its genotoxic effect on erythrocytes in bone marrow.
Six groups each comprising 5 males and 5 females, received a single intraperitoneal injection.
Two groups were dosed with 100 mg/kg body weight, one group was dosed with 50 mg/kg body weight and one group was dosed with 25 mg/kg body weight. After dosing the animals of all the dose levels showed the following toxic signs: lethargy and a hunched posture. The animals of the dose levels of 100 and 50 mg/kg body weight also showed a rough coat and one of the animals dosed with 100 mg/kg body weight showed ataxia.
A vehicle treated group served as negative control, a group treated with a single intraperitoneal injection of cyclophosphamide (CP) at 50 mg/kg body weight served as positive control.
Bone marrow of the groups treated with BLUE MOP 6314 was sampled 24 or 48 hours after dosing. Bone marrow from the negative control group was harvested at 24 hours after dosing only and bone marrow from the positive control group was harvested at 48 hours after dosing only.
Cyclophosphamide, the positive control substance, induced a statistically significant increase in the number of micronucleated polychromatic erythrocytes in both sexes. No increase in the frequency of micronucleated polychromatic erythrocytes was observed in the polychromatic erythrocytes of the bone marrow of animals treated with test item. The animals of the groups treated with 100 mg/kg body weight with test item (males at the 24 and 48 hours sampling time and females at the 48 hours sampling time) showed a slight but variable decrease in the ratio of polychromatic to normochromatic erythrocytes compared to the vehicle controls, indicating that the substance is toxic with respect to the erythropoiesis.
The groups that were treated with cyclophosphamide showed a clear decrease in the ratio of polychromatic to normochromatic erythrocytes compared to the vehicle controls. It is concluded that the substance is not mutagenic in the micronucleus test under the experimental conditions described in this report.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.